Distribution in Pharmaceuticals and Biotechnology Partnering Deal Trends Report 2024: Analysis of Agreements Signed Since 2016 Featuring Over 1,500 Companies – ResearchAndMarkets.com

Distribution in Pharmaceuticals and Biotechnology Partnering Deal Trends Report 2024: Analysis of Agreements Signed Since 2016 Featuring Over 1,500 Companies – ResearchAndMarkets.com




Distribution in Pharmaceuticals and Biotechnology Partnering Deal Trends Report 2024: Analysis of Agreements Signed Since 2016 Featuring Over 1,500 Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Distribution Deals in Pharmaceuticals and Biotechnology 2016 to 2024” report has been added to ResearchAndMarkets.com’s offering.


Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals with details of distribution deals from 2016 to 2024.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse distribution deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents – insights into deal structures
  • Due diligence – assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Distribution Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in distribution dealmaking in the biopharma industry
  • Overview of distribution deal structure
  • Directory of distribution deal records covering pharmaceutical and biotechnology
  • The leading distribution deals by value
  • Most active distribution dealmakers
  • The leading distribution partnering resources

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in distribution dealmaking

2.1. Introduction

2.2. Definition of distribution deals

2.3. Trends in distribution deals since 2016

2.3.1. Distribution dealmaking by year, 2016 to 2024.

2.3.2. Distribution dealmaking by phase of development, 2016 to 2024.

2.3.3. Distribution dealmaking by industry sector, 2016 to 2024.

2.3.4. Distribution dealmaking by therapy area, 2016 to 2024.

2.3.5. Distribution dealmaking by technology type, 2016 to 2024.

2.3.6. Distribution dealmaking by most active company, 2016 to 2024.

2.3.7. Attributes of pure distribution deals

2.3.8. Attributes of distribution in multi-component deals

2.4. Aligning partners to make the distribution agreement work

Chapter 3 – Overview of distribution deal structure

3.1. Introduction

3.2. Distribution agreement structure

3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 – Leading distribution deals

4.1. Introduction

4.2. Top distribution deals by value

Chapter 5 – Top 25 most active distribution dealmakers

5.1. Introduction

5.2. Top 25 most active distribution dealmakers

Chapter 6 – Distribution deals including contracts directory

6.1. Introduction

6.2. Distribution deals with contracts 2016-2024

Deal directory

  • Deal directory – distribution dealmaking by companies A-Z
  • Deal directory – distribution dealmaking by therapy area
  • Deal directory – distribution dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/njcspw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900